• News
  • SAN DIEGO
  • Finance

AstraZeneca falls on disappointing drug study

Shares of AstraZeneca and its partner Rigel Pharmaceuticals Inc. fell Thursday after the companies reported that their experimental rheumatoid arthritis drug failed to show superiority to Abbott's Humira in a midstage study.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!